Clinical Trial Update: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

This document reports results from a Phase 2 expanded-access, open-label study of obinutuzumab plus chlorambucil in previously untreated chronic lymphocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Chlorambucil (chlorambucil)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2016-11-07